Issues discussed:
UsTOO Chicago webinar; Intermittent Hormone Therapy (IHT); Taking a Virtual Group break; resumption after IHT – scan use; MSI; strategies on recurrence; Firmagon vs the agonist LHRH’s; post-surgery with local spread; repeated C-11 sans; nocturia drugs; using medical marijuana; Ciitizen program for medical records; germ line testing with Invitae
Topics discussed:
Intermittent hormone therapy with 2nd line anti-androgens; getting approved for darolutamide (Nubequa) may depend on your screening method; HT, cognition, dementia and more; stretching out Xgeva; scanning at very low PSA levels; darolutamide has positive cognition side effects; focal cryotherapy for metastatic lesions; is oligometastatic radiation, curative, management or palliative?; the meaning of Median Progression Free Survival; FDA Approvals ….. expedited, breakthrough etc – can patient advocacy help?; Ethics of prescribing hormone therapy
And here’s a great article we saw this morning on hormone therapy and cognition by our friend, Dr. Chuck Ryan!
(AnCan strongly endorses this event presented by our prostate cancer partner, UsTOO. It features excellent speakers including one of our ‘all-time favorites’, genitourinary medical oncologist Dr. Alicia Morgans, as well as Dr. Maha Hussein. Please note this event is available LIVE in the Chicago Loop and by WEBINAR.)
UsTOO presents PROSTATE CANCER PATHWAYS
Free Educational Event and Webcast Series
Saturday, November 9
Robert H. Lurie
Medical Research Center
Baldwin Auditorium
303 E. Superior St.
Chicago, IL 60611
10:00 am – 3:00 pm
Featuring experts from the Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital, topics will include:
The conversation will be driven by input and questions from you and others in the prostate cancer community. And it’s all free of charge!
Attend this free event in person and enjoy a heart-healthy/prostate-healthy lunch and give-away items; OR watch the free online webcast providing live audio and video.
Please note that on-site space is limited. We will attempt to accommodate those registering in person on the day of the event, but we cannot guarantee a seat or a free lunch.
For the best Webcast experience, we recommend Google Chrome or Firefox. If you have any questions about joining the webcast, please reach out to support@mainstreamchicago.com.
Register for live and webcast at https://www.mainstreamchicago.com/ustoo-chicago-2019-registration/
BRCA discussion – PROfound, treatment etc; darolutamide; can you measure bone tumors from scans; comparing scanning techniques for disease progression; talk generalities or specifics to your doctor; managing Gleason 9 disease; bicalutamide androgen withdrawal symptoms; Provenge; anticipating symptomatic progression; mindfulness meditation; proton pencil beam radiation therapy PBRT; leg cramps; carboplatin + etoposide for small cell like disease
Tributes to Dr. William ‘Bill’ Burhans PhD https://ancan.org/professor-bill-r-i-p/ ; Medicare coverage for Foundation Medicine genomic sequencing tests; PARP-I niraparib gets FDA breakthrough status; is there a cure in sight for metastatic PCa?; is it worthwhile to genomically sequence Nx (lymphatic) disease?; starting enzalutamide/Xtandi; testosterone recovery post-ADT
On the topic of ‘curing’ metastatic prostate cancer above, two worthwhile articles appeared in my inbox today …. RB or Not RB – That is the Question from our good friend Dr. Charles Ryan. And “What Works for Breast Cancer Should Work for Prostate Cancer, Right?” by Dr. Evan Yu. Be assured there is ample excellent ongoing research aimed at allowing us to justifiably use the ‘C’ word!